Lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under…
Official title: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
This bill appears to be dead.
No action recorded in 1 year, 3 months. The structural status reflects an earlier milestone, not current activity.
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.
Filed in the House
This house bill has been filed and is working its way through Congress. It will need to pass both the House and the Senate, then be signed by the President to become law.
Who introduced this
Gregory Murphy
RepublicanU.S. Representative · NC-3
66 cosponsors — mostly Republicans
Ask AI About This Bill
Get plain-language answers with direct quotes from the bill text.
Your Representatives
Enter your address to see how your representatives voted on this bill.
Your address is only used to find your district and is never saved. See how it works
Votes
Public Opinion
No votes yet — be the first to weigh in.
to cast your vote
Your voice matters — let representatives know where you stand.
Comments
No comments yet. to be the first to weigh in.